PMC:7212965 / 43074-43398 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T99","span":{"begin":121,"end":124},"obj":"Body_part"}],"attributes":[{"id":"A99","pred":"fma_id","subj":"T99","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"ansferases, defined as more than 5 times the ULN, are found in 3%–10%.91 Rates may be higher in patients with concurrent HIV and hepatitis C virus co-infection. In some cases, mild asymptomatic elevations are self-limited and can resolve with continuation of the medication, but re-challenging the medication can also lead t"}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T222","span":{"begin":129,"end":140},"obj":"Disease"},{"id":"T223","span":{"begin":129,"end":138},"obj":"Disease"},{"id":"T224","span":{"begin":150,"end":159},"obj":"Disease"}],"attributes":[{"id":"A222","pred":"mondo_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/MONDO_0005231"},{"id":"A223","pred":"mondo_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"},{"id":"A224","pred":"mondo_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"ansferases, defined as more than 5 times the ULN, are found in 3%–10%.91 Rates may be higher in patients with concurrent HIV and hepatitis C virus co-infection. In some cases, mild asymptomatic elevations are self-limited and can resolve with continuation of the medication, but re-challenging the medication can also lead t"}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T325","span":{"begin":141,"end":146},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"ansferases, defined as more than 5 times the ULN, are found in 3%–10%.91 Rates may be higher in patients with concurrent HIV and hepatitis C virus co-infection. In some cases, mild asymptomatic elevations are self-limited and can resolve with continuation of the medication, but re-challenging the medication can also lead t"}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T199","span":{"begin":129,"end":138},"obj":"Phenotype"}],"attributes":[{"id":"A199","pred":"hp_id","subj":"T199","obj":"http://purl.obolibrary.org/obo/HP_0012115"}],"text":"ansferases, defined as more than 5 times the ULN, are found in 3%–10%.91 Rates may be higher in patients with concurrent HIV and hepatitis C virus co-infection. In some cases, mild asymptomatic elevations are self-limited and can resolve with continuation of the medication, but re-challenging the medication can also lead t"}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"1181","span":{"begin":96,"end":104},"obj":"Species"},{"id":"1188","span":{"begin":121,"end":159},"obj":"Disease"}],"attributes":[{"id":"A1181","pred":"tao:has_database_id","subj":"1181","obj":"Tax:9606"},{"id":"A1188","pred":"tao:has_database_id","subj":"1188","obj":"MESH:D006526"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ansferases, defined as more than 5 times the ULN, are found in 3%–10%.91 Rates may be higher in patients with concurrent HIV and hepatitis C virus co-infection. In some cases, mild asymptomatic elevations are self-limited and can resolve with continuation of the medication, but re-challenging the medication can also lead t"}